Acorda Therapeutics (ACOR) Tops Q2 EPS by 7c
Get Alerts ACOR Hot Sheet
Price: $13.50 +8.87%
EPS Growth %: -139.7%
Financial Fact:
Provision for income taxes: -3.02M
Today's EPS Names:
BFRI, HCTI, IMPM, More
EPS Growth %: -139.7%
Financial Fact:
Provision for income taxes: -3.02M
Today's EPS Names:
BFRI, HCTI, IMPM, More
Join SI Premium – FREE
Acorda Therapeutics (NASDAQ: ACOR) reported Q2 EPS of $0.19, $0.07 better than the analyst estimate of $0.12. Revenue for the quarter came in at $65.28 million versus the consensus estimate of $66.29 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Embraer (ERJ) Tops Q4 EPS by 43c; offers guidance
- Augmedix, Inc. (AUGX) Tops Q4 EPS by 1c
- Singular Genomics Systems, Inc. (OMIC) Reports In-Line Q4 EPS
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!